Specialty: UK group continues to influence local managed care discussions
Medicare & Reimbursement Advisor Weekly, June 17, 2009
The National Institute for Health and Clinical Excellence (NICE) continues to be an important resource for U.S. managed care, particularly in the specialty pharmacy and oncology arena. This year, the UK government organization approved Revlimid for multiple myeloma (with the condition that Celgene meets the cost of therapy after 26 cycles), and Sutent for kidney cancer, but Alimta was not approved. In recent MRAW editions, we have discussed the role of NICE in managed care decisions. Future issues will include interviews with your plan customers about their views on NICE.
Here is a short list (below) of upcoming guidelines NICE is expected to release in the next 12 months.
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- Capturing all necessary codes for IUD insertion and removal can be challenging
- QA:Coding multiple initial infusions
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- OB services: Coding inside and outside of the package
- HIPAA Q&A: Level of encryption needed for email
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- Q&A tackles coding questions about injections and infusions
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Hospitalist-surgeon comanagement has no effect on outcomes
- Case Management Monthly, June 2012
- Searched